CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER

Clinical trials for CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER explained in plain language.

Never miss a new study

Get alerted when new CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER trials appear

Sign up with your email to follow new studies for CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Experimental drug combo targets Tough-to-Treat bile duct cancer

Disease control Not yet recruiting

This study is testing whether adding an experimental drug called QLS31905 to standard chemotherapy helps control advanced bile duct cancer that has a specific marker called CLDN18.2. Researchers will enroll 120 patients who haven't received prior treatment for their advanced canc…

Matched conditions: CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER

Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Apr 02, 2026 02:41 UTC

CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER

Get alerted when new CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER trials appear

Experimental drug combo targets Tough-to-Treat bile duct cancer